glp 1 agonist ilaçlar GLP-1 ilaçları ABD ekonomisini hızlandırabilir - Goldman Sachs 📌 İĞNE YERİNE HAP: AB'DEN
Description
GLP-1s (glucagon-like peptide-1 agonists) are a class of medications that help manage blood sugar levelsas well as reduce the risk of cardiovascular disease (like stroke and heart attack), and obesity
Two large, randomized control trials investigating liraglutide and semaglutide have suggested worsening retinopathy as an adverse effect of GLP-1RA use
They have both gone through extensive clinical programmes, including cardiovascular outcomes trials, and have shown beneficial effects [22, 26, 27]
The introduction of generics, such as Glenmarks liraglutide biosimilar launched at dramatically lower prices, reflects the push toward affordability and broader access in a cost-conscious market
These often improve over time
Ozempic (semaglutide 0.5mg, 1mg, or 2mg weekly injection) is FDA-approved for type 2 diabetes management, not weight loss
